Elan and Biogen Idec Preparing to Appeal Ruling on European ...
PharmaLive.com (press release) - Newtown,PA,USA
An application for approval of TYSABRI(R) (natalizumab) for treatment of moderate to severe Crohn's disease was filed in the US on December 15, 2006. ...
See all stories on this topic

Firms to appeal EU advisers' Tysabri vote
United Press International - USA
Sold under the brand name Tysabri, the treatment has previously generated controversy when it was approved in the United States and Europe to treat multiple ...
See all stories on this topic

Elan, Biogen Idec to appeal European ruling on Crohn's disease ...
Forbes - NY,USA
... for Medicinal Products for Human Use has adopted a negative opinion on their application for the use of Tysabri as a treatment for Crohn's disease. ...
See all stories on this topic

TechMARK movers: Elan fails to win Tysabri approval
ShareCast - London,UK
LONDON (SHARECAST) - Pharmaceutical firm Elan led today's fallers after it said the European Medicines Agency has refused to approve the use of its Tysabri ...
See all stories on this topic

European regulators reject Tysabri for Crohn's
Reuters - USA
LONDON/BOSTON, July 19 (Reuters) - European drug regulators have recommended against the use of Tysabri, a multiple sclerosis drug made by Biogen Idec Inc. ...
See all stories on this topic

Biotech plant gets go-ahead
North County Times - Escondido,CA,USA
Biogen Idec intended to use the plant to make Tysabri, a drug to treat multiple sclerosis. Tysabri sales were on an upswing, and the company needed more ...
See all stories on this topic